Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : SNY save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 1.04%
H: 1.53%
C: 1.37%
ALNY | $146.07 0.19% 0.18% 540K
|
Health Technology
|
| O: -3.53%
H: 0.0%
C: -1.2%
results phase 3
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
evkeeza children cholesterol trial phase 3 rare
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | News | $128.64 2.7% -1.0% 3.5M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.37 -2.27% -7.02% 2
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial
Published: 2022-03-03 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -6.92%
H: 1.86%
C: 1.86%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
trial disease phase 3
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
| Email alert
Add to watchlist
dupixent urticaria phase 3 hiv
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Published: 2022-01-19 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
dupixent trial positive phase 3
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
Published: 2021-12-15 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 4.76%
H: 2.5%
C: 2.5%
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
covid-19 trial covid positive vaccine phase 3
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
phase 3
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ALNY | $146.07 0.19% 0.18% 540K
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
results phase 3
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Published: 2021-12-08 (Crawled : 23:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -0.62%
H: 2.7%
C: 2.42%
dupixent positive results children phase 3
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | News | $88.49 0.55% 0.59% 1K
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: -0.31%
GSK | News | $41.24 1.6% 0.0% 1.6K
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
covid treatment phase 3 trial
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 3.88%
H: 0.78%
C: 0.68%
covid casirivimab phase 3
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
LUCY | $0.2545 9.93% 13.94% 66K
|
n/a
MARA | $19.44 10.77% 10.28% 630K
|
Commercial Services
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
Your saved searches
Save your searches and get alerts when important news are released.